FY2026 EPS Estimates for Medtronic Lifted by Leerink Partnrs

Key Points

• FY2026 EPS Estimates: Leerink Partners has raised Medtronic's FY2026 earnings per share estimate from $5.54 to $5.64, maintaining a "Strong-Buy" rating on the stock.
• Quarterly Earnings Performance: Medtronic reported $1.26 EPS for the recent quarter, surpassing the consensus estimate of $1.23, with a revenue increase of 7.7% year-over-year, totaling $8.58 billion.
• Upcoming Dividend: Medtronic will pay a quarterly dividend of $0.71 on October 17th, translating to an annualized dividend yield of 3.1% for shareholders of record as of September 26th.

Medtronic PLC (NYSE:MDT - Free Report) - Analysts at Leerink Partnrs increased their FY2026 earnings per share (EPS) estimates for shares of Medtronic in a research note issued to investors on Wednesday, August 20th. Leerink Partnrs analyst M. Kratky now expects that the medical technology company will earn $5.64 per share for the year, up from their previous forecast of $5.54. Leerink Partnrs has a "Strong-Buy" rating on the stock. The consensus estimate for Medtronic's current full-year earnings is $5.46 per share. Leerink Partnrs also issued estimates for Medtronic's FY2028 earnings at $6.54 EPS, FY2029 earnings at $7.02 EPS and FY2030 earnings at $7.53 EPS.

Medtronic (NYSE:MDT - Get Free Report) last released its quarterly earnings data on Tuesday, August 19th. The medical technology company reported $1.26 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.23 by $0.03. Medtronic had a net margin of 13.63% and a return on equity of 14.56%. The firm had revenue of $8.58 billion for the quarter, compared to analysts' expectations of $8.37 billion. During the same quarter last year, the business posted $1.23 earnings per share. The company's revenue for the quarter was up 7.7% compared to the same quarter last year. Medtronic has set its FY 2026 guidance at 5.600-5.660 EPS.

A number of other research firms also recently issued reports on MDT. Wolfe Research raised Medtronic from an "underperform" rating to a "peer perform" rating in a research note on Monday, June 30th. Leerink Partners started coverage on shares of Medtronic in a research note on Monday, June 16th. They set an "outperform" rating and a $110.00 price target on the stock. Wall Street Zen cut shares of Medtronic from a "buy" rating to a "hold" rating in a research note on Saturday, August 9th. Evercore ISI upped their target price on shares of Medtronic from $103.00 to $106.00 and gave the company an "outperform" rating in a research report on Tuesday, July 8th. Finally, Sanford C. Bernstein lifted their price target on Medtronic from $97.00 to $98.00 and gave the stock an "outperform" rating in a research report on Wednesday. Two equities research analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating and eight have assigned a Hold rating to the company. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus price target of $101.15.

Medtronic Stock Performance

Shares of NYSE MDT opened at $91.1180 on Friday. The company has a market cap of $116.80 billion, a P/E ratio of 25.10, a P/E/G ratio of 2.40 and a beta of 0.80. Medtronic has a 52-week low of $79.29 and a 52-week high of $96.25. The company has a debt-to-equity ratio of 0.53, a quick ratio of 1.42 and a current ratio of 1.85. The firm's fifty day moving average is $89.62 and its two-hundred day moving average is $88.02.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of MDT. 1248 Management LLC bought a new position in Medtronic in the 1st quarter valued at $26,000. Burkett Financial Services LLC grew its holdings in shares of Medtronic by 185.0% in the first quarter. Burkett Financial Services LLC now owns 285 shares of the medical technology company's stock worth $26,000 after purchasing an additional 185 shares during the last quarter. Delos Wealth Advisors LLC bought a new position in shares of Medtronic in the second quarter worth about $27,000. Columbia River Financial Group LLC purchased a new position in Medtronic in the 1st quarter worth about $28,000. Finally, Twin Tree Management LP bought a new stake in Medtronic during the 1st quarter valued at about $29,000. Institutional investors own 82.06% of the company's stock.

Medtronic Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, October 17th. Shareholders of record on Friday, September 26th will be paid a $0.71 dividend. The ex-dividend date of this dividend is Friday, September 26th. This represents a $2.84 annualized dividend and a yield of 3.1%. Medtronic's dividend payout ratio (DPR) is presently 78.24%.

Medtronic Company Profile

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.